Stempoint Capital LP: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1952142) · Explore on the interactive board
Stempoint Capital LP disclosed 73 US equity positions worth $577.9m in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is TNGX at 6.6% of the reported book, followed by ABVX, RVMD. The top ten holdings are 41.2% of the book, and the portfolio behaves like about 37 equal-weight positions. Versus the prior filing it opened 25 new positions, added to 18, reduced 28 and exited 22. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Stempoint Capital LP own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 25 new, 18 added, 28 reduced, 22 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | TNGX TANGO THERAPEUTICS INC | Healthcare | 6.6% | $38.2m | 1,223,019 | 509% | added |
| 2 | ABVX ABIVAX SA | Healthcare | 6.5% | $37.8m | 283,657 | -10% | reduced |
| 3 | RVMD REVOLUTION MEDICINES INC | Healthcare | 5.2% | $30.0m | 159,943 | -43% | reduced |
| 4 | ERAS ERASCA INC | Healthcare | 5.0% | $28.7m | 1,565,913 | 553% | added |
| 5 | TYRA TYRA BIOSCIENCES INC | Healthcare | 3.5% | $20.2m | 632,754 | 228% | added |
| 6 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 3.4% | $19.6m | 200,851 | 135% | added |
| 7 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 3.0% | $17.6m | 346,914 | -5% | reduced |
| 8 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 2.8% | $16.3m | 602,686 | 13% | added |
| 9 | BHVN BIOHAVEN LTD | Healthcare | 2.7% | $15.8m | 1,064,200 | -33% | reduced |
| 10 | SRZN SURROZEN INC | 2.4% | $13.8m | 602,798 | 15% | added | |
| 11 | KINIKSA PHARMACEUTICALS INTL | 2.3% | $13.4m | 209,234 | – | new | |
| 12 | SRRK SCHOLAR ROCK HLDG CORP | Healthcare | 2.3% | $13.2m | 239,146 | -77% | reduced |
| 13 | ALKS ALKERMES PLC | Healthcare | 2.2% | $13.0m | 248,015 | 208% | added |
| 14 | TRAX FIRST TRACKS BIOTHERAPEUTICS | 2.2% | $12.5m | 622,723 | – | new | |
| 15 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 2.2% | $12.5m | 37,243 | -34% | reduced |
| 16 | ROIV ROIVANT SCIENCES LTD | Healthcare | 2.1% | $12.3m | 348,408 | -10% | reduced |
| 17 | BIOA BIOAGE LABS INC | 2.0% | $11.4m | 464,171 | 37% | added | |
| 18 | CGON CG ONCOLOGY INC | Healthcare | 2.0% | $11.3m | 159,349 | -23% | reduced |
| 19 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 1.9% | $11.1m | 116,461 | – | new |
| 20 | IMVT IMMUNOVANT INC | Healthcare | 1.8% | $10.7m | 276,527 | -63% | reduced |
| 21 | CELC CELCUITY INC | Healthcare | 1.8% | $10.3m | 98,203 | 64% | added |
| 22 | RLMD RELMADA THERAPEUTICS INC | Healthcare | 1.7% | $10.1m | 1,460,093 | 144% | added |
| 23 | CLYM CLIMB BIO INC | Healthcare | 1.7% | $9.7m | 742,745 | – | new |
| 24 | SYRE SPYRE THERAPEUTICS INC | Healthcare | 1.6% | $9.5m | 106,926 | -36% | reduced |
| 25 | ZURA ZURA BIO LTD | Healthcare | 1.4% | $8.1m | 1,368,215 | 82% | added |
| 26 | INFLARX NV | 1.3% | $7.2m | 3,228,255 | – | new | |
| 27 | AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 1.2% | $6.9m | 384,304 | -43% | reduced |
| 28 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 1.1% | $6.6m | 178,412 | -30% | reduced |
| 29 | OVID OVID THERAPEUTICS INC | Healthcare | 1.1% | $6.5m | 2,417,283 | – | new |
| 30 | EQ EQUILLIUM INC | 1.1% | $6.5m | 2,016,607 | – | new | |
| 31 | DFTX DEFINIUM THERAPEUTICS INC | Healthcare | 1.1% | $6.5m | 137,124 | -58% | reduced |
| 32 | CYTK CYTOKINETICS INC | Healthcare | 1.1% | $6.4m | 75,603 | -42% | reduced |
| 33 | DMRA DAMORA THERAPEUTICS INC | Healthcare | 1.0% | $5.6m | 216,194 | – | new |
| 34 | IVA INVENTIVA SA | 0.9% | $5.4m | 1,426,320 | – | new | |
| 35 | IPSC CENTURY THERAPEUTICS INC | Healthcare | 0.9% | $5.3m | 2,146,182 | – | new |
| 36 | AURA AURA BIOSCIENCES INC | 0.9% | $5.1m | 714,280 | – | new | |
| 37 | EYPT EYEPOINT INC | Healthcare | 0.8% | $4.8m | 338,471 | -58% | reduced |
| 38 | ASMB ASSEMBLY BIOSCIENCES INC | Healthcare | 0.8% | $4.7m | 170,378 | -8% | reduced |
| 39 | WHWK WHITEHAWK THERAPEUTICS INC | Healthcare | 0.8% | $4.7m | 1,021,037 | 9% | added |
| 40 | XENE XENON PHARMACEUTICALS INC | Healthcare | 0.8% | $4.6m | 76,075 | -46% | reduced |
| 41 | UNIQURE NV | 0.7% | $4.1m | 88,115 | 13% | added | |
| 42 | CMPS COMPASS PATHWAYS PLC | Healthcare | 0.7% | $4.0m | 284,769 | – | new |
| 43 | AVALYN PHARMACEUTICALS INC | 0.7% | $3.9m | 118,000 | – | new | |
| 44 | MPLT MAPLIGHT THERAPEUTICS INC | 0.7% | $3.8m | 106,906 | 7% | added | |
| 45 | ALMS ALUMIS INC | Healthcare | 0.7% | $3.8m | 135,736 | -41% | reduced |
| 46 | AXSM AXSOME THERAPEUTICS INC. | Healthcare | 0.7% | $3.8m | 15,375 | – | new |
| 47 | GLUE MONTE ROSA THERAPEUTICS INC | Healthcare | 0.6% | $3.7m | 153,544 | – | new |
| 48 | ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 0.6% | $3.6m | 143,167 | -41% | reduced |
| 49 | SLDB SOLID BIOSCIENCES INC | Healthcare | 0.6% | $3.6m | 358,780 | 84% | added |
| 50 | PSNL PERSONALIS INC | Healthcare | 0.6% | $3.3m | 247,783 | – | new |
What did Stempoint Capital LP sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| SNDX SYNDAX PHARMACEUTICALS INC | 25.3% | $28.4m |
| MBX MBX BIOSCIENCES INC | 13.3% | $14.9m |
| DYN DYNE THERAPEUTICS INC | 8.2% | $9.2m |
| EWTX EDGEWISE THERAPEUTICS INC | 8.2% | $9.2m |
| DNLI DENALI THERAPEUTICS INC | 7.3% | $8.2m |
| NRIX NURIX THERAPEUTICS INC | 4.4% | $4.9m |
| EVMN EVOMMUNE INC | 3.9% | $4.4m |
| FTH SENSEI BIOTHERAPEUTICS INC | 3.7% | $4.2m |
| JNJ JOHNSON & JOHNSON | 3.4% | $3.8m |
| XFOR X4 PHARMACEUTICALS INC | 3.1% | $3.5m |
| PCVX VAXCYTE INC | 3.1% | $3.4m |
| IVVD INVIVYD INC | 2.2% | $2.4m |
| JBIO JADE BIOSCIENCES INC | 1.9% | $2.2m |
| TWST TWIST BIOSCIENCE CORP | 1.8% | $2.0m |
| AVTX AVALO THERAPEUTICS INC | 1.8% | $2.0m |
| IONS IONIS PHARMACEUTICALS INC | 1.8% | $2.0m |
| IMCR IMMUNOCORE HLDGS PLC | 1.7% | $1.9m |
| FBRX FORTE BIOSCIENCES INC | 1.3% | $1.5m |
| LPCN LIPOCINE INC NEW | 1.1% | $1.3m |
| EW EDWARDS LIFESCIENCES CORP | 1.0% | $1.2m |
| CAPR CAPRICOR THERAPEUTICS INC | 1.0% | $1.1m |
| STRO SUTRO BIOPHARMA INC | 0.5% | $580.3k |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 80.4% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Stempoint Capital LP's portfolio?
Across every quarter Stempoint Capital LP has filed, its median largest position is 8.2% of the book and its median top-ten weight is 43.3%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 22.0 completed holding spells, the median lasted 1.0 quarters; 73.0 positions are still open and their final length is unknown.